These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 15007146

  • 1. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
    Morra VB, Coppola G, Orefice G, De Michele G, Vacca G, Filla A, Bonavita V.
    Neurology; 2004 Mar 09; 62(5):829-30. PubMed ID: 15007146
    [No Abstract] [Full Text] [Related]

  • 2. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A, Bethke F, Lüdemann P, Stögbauer F.
    Neurology; 1999 Nov 10; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract] [Full Text] [Related]

  • 3. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R.
    Clin Neurol Neurosurg; 2002 Jul 10; 104(3):259-64. PubMed ID: 12127665
    [No Abstract] [Full Text] [Related]

  • 4. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
    Alsalameh S, Manger B, Kern P, Kalden J.
    Arthritis Rheum; 1998 Apr 10; 41(4):754. PubMed ID: 9550494
    [No Abstract] [Full Text] [Related]

  • 5. A nexus between lipids and multiple sclerosis?
    Zorzon M.
    J Neurol Neurosurg Psychiatry; 2013 Nov 10; 84(11):1181. PubMed ID: 23595948
    [No Abstract] [Full Text] [Related]

  • 6. [Modifications of the lipid metabolism induced by interferon beta in multiple sclerosis patients and its relationship with the disease activity].
    Ara JR, López A, Martín J, Alarcia R, Oliván JA, de Val V.
    Neurologia; 2004 Sep 10; 19(7):359-63. PubMed ID: 15273882
    [Abstract] [Full Text] [Related]

  • 7. Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug.
    Longthorne PN.
    BMJ; 1996 Nov 16; 313(7067):1263. PubMed ID: 8939141
    [No Abstract] [Full Text] [Related]

  • 8. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G.
    Arch Neurol; 2001 Aug 16; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract] [Full Text] [Related]

  • 9. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
    Cardy P.
    BMJ; 1996 Nov 16; 313(7067):1263. PubMed ID: 8939142
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of multiple sclerosis with interferon beta-1 b.
    Abdul-Ahad A, Shah S, Galazka A.
    Neurology; 1997 Aug 16; 49(2):641-2. PubMed ID: 9270626
    [No Abstract] [Full Text] [Related]

  • 11. Experiences with interferon-beta-1b treatment in MS after three year follow-up.
    Bencsik K, Rajda C, Füvesi J, Járdánházy T, Török M, Vécsei L.
    Swiss Med Wkly; 2002 May 04; 132(17-18):237. PubMed ID: 12087490
    [No Abstract] [Full Text] [Related]

  • 12. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP, Moreira MA, Mendes MF, Lana-Peixoto MA.
    Arq Neuropsiquiatr; 2000 Sep 04; 58(3A):769-76. PubMed ID: 10973126
    [Abstract] [Full Text] [Related]

  • 13. Contemporary immunomodulatory therapy for multiple sclerosis.
    Rudick RA.
    J Neuroophthalmol; 2001 Dec 04; 21(4):284-91. PubMed ID: 11756861
    [Abstract] [Full Text] [Related]

  • 14. Interferon beta in multiple sclerosis.
    Richards RG.
    BMJ; 1996 Nov 09; 313(7066):1159. PubMed ID: 8916730
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL, Khachanova NV, Davydovskaia MV, Popova NF, Gusev EI.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008 Nov 09; 108(4):24-6. PubMed ID: 18567192
    [No Abstract] [Full Text] [Related]

  • 16. Use of interferon beta 1b for multiple sclerosis. Patients will put up with side effects because of their desire to beat the disease.
    Chellingsworth M.
    BMJ; 1996 Nov 16; 313(7067):1263. PubMed ID: 8939140
    [No Abstract] [Full Text] [Related]

  • 17. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
    Blake G, Murphy S.
    Neurology; 1997 Dec 16; 49(6):1747-8. PubMed ID: 9409387
    [No Abstract] [Full Text] [Related]

  • 18. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J, White R.
    Mult Scler; 1997 Dec 16; 3(6):402. PubMed ID: 9493643
    [No Abstract] [Full Text] [Related]

  • 19. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K, Conway K.
    Rehabil Nurs; 1997 Dec 16; 22(2):62-6, 81. PubMed ID: 9110845
    [Abstract] [Full Text] [Related]

  • 20. Why interferon beta 1b was licensed is a mystery.
    Harvey P.
    BMJ; 1996 Aug 03; 313(7052):297-8. PubMed ID: 8704553
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.